(RTTNews) - Johnson & Johnson (JNJ), a healthcare company focused on innovative medicines and medical technologies, reported two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra) in adults and adolescents aged 12 years and older with moderate-to-severe plaq
Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis
(RTTNews) - Johnson & Johnson (JNJ), a healthcare company focused on innovative medicines and medical technologies, repo...
By Dhallo News · October 9, 2026 at 5:32 PM IST
Have feedback on this article?Report error or suggestion
